Other studies have demonstrated the involvement of myeloid cell cathepsin X in AD, defining it as a potential target for ameliorating mid-to-late-stage disease in APPSWE/PS1 ΔE9 mice [121]. This evidence concerns the gene CTSZ and Alzheimer disease.